NKGen Biotech, Inc. (NKGN)
NASDAQ: NKGN · Real-Time Price · USD
0.570
+0.122 (27.12%)
At close: Feb 21, 2025, 4:00 PM
0.500
-0.070 (-12.20%)
After-hours: Feb 21, 2025, 7:59 PM EST
Company Description
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.
Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.
The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
NKGen Biotech, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Paul Y. Song |
Contact Details
Address: 3001 Daimler Street Santa Ana, California 92705 United States | |
| Phone | 949-396-6830 |
| Website | nkgenbiotech.com |
Stock Details
| Ticker Symbol | NKGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001845459 |
| CUSIP Number | 65488A101 |
| ISIN Number | US65488A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Y. Song M.D. | Chief Executive Officer and Chairman |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer |
| James A. Graf | Interim Chief Financial Officer |
| Yoonmi Kang | SVice President of Technical Ops and Development |
| Irene Chang | SVice President, Human Resources and Corporate Culture |
| Denise A. Chua CLS, MBA, MT (ASCP) | SVice President of Corporate Affairs |
| Ryan Park C.F.A. | Executive Vice President of Financial Planning and Analysis and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 3, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 24, 2025 | PRE 14A | Other preliminary proxy statements |
| Jan 8, 2025 | 8-K | Current Report |
| Jan 2, 2025 | 8-K | Current Report |
| Jan 2, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |